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ABSTRACT
Tick-borne encephalitis and West Nile fever are endemic flavivirus diseases in Europe. Climate change,
virus evolution, and social factors may increase the risk of these flavivirus infections and may lead to the
emergence of other flaviviruses in Europe that are endemic in (sub)tropical regions of the world. Control
of the spread of flaviviruses is very difficult considering the cycling of flaviviruses between arthropod
vectors and animal reservoir hosts. The increasing threat of flavivirus infections emphasizes the necessity
of a sustainable vector surveillance system, an active animal health surveillance system and an adequate
human surveillance system for early detection of flavivirus infections. Vaccination is the most important
approach to prevent flavivirus infections. Effective inactivated whole virus vaccines against tick-borne
encephalitis (TBE) infection are available. Implementation of TBE vaccination based on favorable cost-
effectiveness estimates per region and per target group can reduce the disease burden of TBE infection.
At present, several West Nile virus (WNV) vaccine candidates are in various stages of clinical development.
A major challenge for WNV vaccine candidates is to demonstrate efficacy, because of the sporadic nature
of unpredictable WNV outbreaks. Universal WNV vaccination is unlikely to be cost-effective, vaccination of










The Flaviviridae family comprises more than 70 different viruses,
many of which are arthropod-borne and transmitted by either
mosquitoes or ticks. With respect to occurrence and disease
impact, the most important flaviviruses are yellow fever virus
(YFV), dengue virus (DENV), Japanese encephalitis virus (JEV),
West Nile virus (WNV), tick-borne encephalitis virus (TBEV),
and Zika virus. With the exception of members of TBEV that
are transmitted by ticks, mosquitoes transmit the major human
pathogenic flaviviruses. In Europe, tick-borne encephalitis and
West Nile fever are endemic flavivirus diseases.1,2
It is extremely difficult to control the spread of flaviviruses,
because most flavivirus life cycles are maintained between
arthropod vectors and reservoir hosts in the absence of
humans. Moreover, no specific antivirals are available. Vaccina-
tion is considered the most important intervention to prevent
flavivirus infections. Effective inactivated or live attenuated
whole virus vaccines against yellow fever, Japanese encephalitis,
and tick-borne encephalitis infections are available, but vac-
cines against West Nile virus, dengue virus, and Zika virus are
still in development.1,2
Clinical diagnosis of flavivirus infection is often not reliable
because the manifestations of the disease are often not specific.
Therefore, laboratory diagnosis, based on the presence of serum
antibodies against flaviviruses, is needed to confirm the etiology
of the disease. Usually specific IgM- and IgG-serum antibodies
are determined by enzyme-linked immuno-sorbent assay
(ELISA), since these antibodies are detectable in practically
every case at the time of hospitalization.3,4 Positive ELISA
results are confirmed by flavivirus neutralization tests. How-
ever, serologic testing is challenging due to cross-reactivity
between the flaviviruses.3–5 Virus isolation from blood, or the
detection of specific nucleic acids in blood or cerebrospinal
fluid by reverse-transcriptase polymerase chain reaction
(RT-PCR) overcomes the problem of serological cross-
reactivity, but is only successful during the first viremic phase
of the disease, before seroconversion.3 With the onset of the
second phase of disease, the virus can only be detected from
the cerebrospinal fluid.
Neutralizing antibodies have a critical role in the long-term
protection from disease and at present their measurement pro-
vides the best correlate of flavivirus immunity.2,6 The flavivirus
envelope (E) protein, involved in host cell attachment and mem-
brane fusion, is the major target of virus neutralizing antibod-
ies.2,5,6 The amino acid sequence identity in the E protein ranges
from 40–44% for unrelated flaviviruses to 60–70% within closely
related flaviviruses. The extent and duration of cross-neutraliza-
tion and even cross-protection is strongly dependent on the
degree of amino acid similarity in the E protein. Infection with
any one of the four DENV serotypes induces life-long protection
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against the same serotype but only for few months against the
other serotypes.2 A human cohort study with sera from persons
with a history of vaccination against TBEV, JEV and YFV
showed that some individuals vaccinated against TBEV and JEV
were able to neutralize WNV.7 The presence of non-neutralizing
antibodies or neutralizing antibodies at suboptimal concentra-
tions, however, may cause antibody-dependent enhancement of
infection (ADE). These antibodies can facilitate virus entry
through Fc receptor binding leading to increased infection
instead of protection. The most clearly established role for ADE
in vivo exists for DENV.2,8 For the development of flavivirus vac-
cines, it is therefore important to rule out ADE induction by the
vaccine. On the other hand, flaviviral cross-reactivity could help
to develop wide spectrum vaccines against flaviviruses.
In this article the challenges for vaccination and preparations
that should be considered to protect for the endemic flavivirus
diseases in Europe, i.e. TBE and West Nile fever, are addressed.
Tick borne encephalitis virus
Virus and transmission
TBE is an infectious disease involving the central nervous sys-
tem caused by the tick-borne encephalitis virus (TBEV). There
are three distinct subtypes of TBEV, i.e. the European subtype
(TBEV-Eu), widely distributed in Western, Central, Northern,
and Eastern Europe; the Far Eastern subtype (TBEV-Fe), circu-
lating in China, Japan, and eastern Russia; and the Siberian
subtype (TBEV-Si), present in Siberia and some parts of Rus-
sia.9 TBEV is maintained in nature by numerous species of res-
ervoir hosts, particularly rodents, and various vector tick
species. Rodents act as maintenance, amplifying and reservoir
hosts. Humans and horses are dead-end hosts. For human
infections, viruses are transmitted by tick bites (adult and
nymph) or intake of non-pasteurized dairy products.3,9 Ixodes
ricinus is the main tick vector for TBEV-Eu, whereas Ixodes
persulcatus is the main vector for TBEV-Fe and TBEV-Si,
although TBEV can be transmitted by as many as 11 different
tick species.9 Once infected, the tick is infective for its lifespan
that can be up to 3 years.10 TBE virus has been shown to spread
from infected ticks to humans within hours. TBE cases occur in
humans most frequently during the highest period of tick activ-
ity (between April and November) (Fig. 1).11
Clinical disease and incidence
Clinical manifestations following infection with TBE virus can vary
between TBEV subtypes. About 10–30% of human infections are
symptomatic.1 Typical TBEV infection is biphasic in approxi-
mately 75% of patients.12,13 The first symptoms occur on average
7 days after a tick bite, although incubation of up to 28 days has
been described.12–14 Themedian duration of the first stage of illness
is 5 days followed by an asymptomatic period of approximately one
week before the second phase. In the first stage, the dominant
symptoms are fever, headache, fatigue, myalgia, nausea, and/or
vomiting.1,12,14 Significant morbidity and mortality is associated
with the second phase of disease. The clinical spectrum ranges
from mild to severe meningitis (50%), severe meningoencephalitis
(40%) and meningoencephalomyelitis (10%).12,13 Following
encephalitis, up to 40% of cases result in long-term neurological
sequelae, which include diverse manifestations such as spinal nerve
paralysis, neuropsychiatric complaints, dysphasia, ataxia and pare-
sis.1,15 TBEV-Fe infection is more frequently associated with severe
neurologic disease, relatively high case fatality rate and an increased
propensity for neurological sequelae in survivors. Fatality rates are
reported to be  20%, 6–8%, and 1–2% in TBEV-Fe, TBEV-Si,
and TBEV-Eu infections, respectively.1 According to the European
Figure 1. Confirmed TBE cases per 100,000 inhabitants in Europe per country, 2014.11
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Surveillance System, the number of confirmed TBE cases in 2014
was 1,986. The proportion of confirmed TBE cases was higher in
men (59.2%). The majority of cases belonged to the age group 45–
65 years (40.4%), i.e. 0.62 cases per 100,000 population, followed
by the age group  65 years (0.42 cases per 100,000 population).
The lowest rates were observed in children.11 The incidence of clin-
ical cases is reported to be between 10,000 and 15,000 per year
worldwide, though it is probably underestimated, because notifica-
tion of the disease is not mandatory in all countries.9 Numbers of
reported TBE cases have increased in recent decades, because of cli-
mate change, increased outdoor activities and improved surveil-
lance systems.1
Vaccines
At present, there is no drug with demonstrated efficacy avail-
able against TBEV. Other than the avoidance of exposure to
the bite of an infected tick, vaccination is the most effective
means of disease prevention. Different inactivated whole virus
vaccines produced in Europe and Russia can prevent TBE.2,10
The effectiveness of both the European and Russian vaccine is
very high: it reaches 98% when the proper vaccination sched-
ule is applied, and has led to a dramatic decline of disease
incidence in the vaccinated population.2 The primary immu-
nization schedule includes 3 doses; booster doses are recom-
mended at varying intervals in different countries (see Table 1
for WHO recommended immunization schedules against
TBE). The first TBEV vaccine, FSME-IMMUN, an inacti-
vated whole virus vaccine (TBEV-Eu serotype) produced on
primary chicken embryo cells was approved and used in Aus-
tria since 1976. For pediatric use, FSME-IMMUN(Junior)
was launched in 2003.1 Encepur, also an inactivated whole
virus vaccine (TBEV-Eu subtype), was licensed in 1991. For
pediatric use, EncepurK was approved in 1994. Two addi-
tional vaccines manufactured in Russia, TBE-Moscow and
EnceVir, based on strains of TBEV-Fe subtype, are only
available in Russia and some neighboring countries. All
TBEV vaccines showed to give high seroconversion rates (88–
100%) following three immunizations. Cross-neutralizing
antibodies against TBEV-Fe and TBEV-Si were detected in
humans immunized with FSME-IMMUN containing TBEV-
Eu antigens. In general, it is assumed that cross-protective
immunity against all three serotypes can be induced by any
TBEV vaccine.1 TBEV vaccination was successfully
implemented into routine immunization programs; the inci-
dence rate of TBEV infection in Austria has declined from
5.7/100,000 population (average from 1972–1981) to 0.9/
100,000 (average of 2002–2011) (Table 1).16
West Nile virus
Virus and transmission
West Nile virus (WNV) is a flavivirus attracting worldwide
attention because it has spread rapidly across the US since its
first appearance in New York City in 1999. Presently, WNV is
categorized into five genetic distinct lineages, though most iso-
lates fall into lineage 1, clade 1a or lineage 2.17 The New York
1999 WNV strain belongs to lineage 1, clade 1a. Viruses of
clade 1a are found worldwide. Lineage 2 comprises virus iso-
lates from Sub-Saharan Africa and Madagascar and emerged in
2004 in central Europe and southern European countries.18,19
Humans are dead-end hosts.18 Human infection is most often
the result of bites from infected mosquitoes, usually in the sum-
mer season or in early autumn. WNV is maintained in mos-
quito populations through vertical transmission (adults to
eggs.20,21 Mosquitoes become infected when they feed on
infected birds, the prime reservoir host. The virus will accumu-
late and replicate in the salivary glands of mosquitoes, which
will result in high viremia in the saliva. During feeding after a
mosquito bite, the virus can be transmitted to mammalian
hosts, where it can multiply and cause illness. Mosquitoes of
the genus Culex are the principal vectors of WNV, in particular
Cx. pipiens.20 Introduction of WNV into new areas is generally
considered to be initiated by migratory birds.
Clinical disease and incidence
Most cases of WNV infection are subclinical or asymptomatic,
approximately 20–30% will present as West Nile fever
(WNF).17,22 WNF cases are considerably underreported, since
routine diagnostic testing is not recommended and many
patients do not seek medical care.23 Most symptomatic patients
experience an acute systemic febrile illness that often includes
headache, weakness, myalgia, or arthralgia; gastrointestinal
symptoms and a transient maculopapular rash are also com-
monly reported. Less than 1% of the infected persons develop
more severe West Nile neuroinvasive disease (WNND).17,23,24
Table 1. Immunization schedules for tick-borne encephalitis vaccines according to WHO recommendations.
Basic immunization: conventional
schedule (dose 1 on day 0)
Basic immunization: rapid
schedule (dose 1 on day 0)
Vaccine 2nd dose (mo) 3rd dose (mo) 2nd dose 3rd dose 4th dose (mo) 1st booster
Subsequent
boosters (yrs)
FSME-Immun 1–3 mo 5–12 mo 14 d 5–12 mo — 3 yrs 5y
Encepur 1–3 mo (14 d) 9–12 mo 7 d 21 d — 12–18 mo 5y
TBE-Moscow vaccine 1–7 mo 12 mo — — — 3 yrs 3
EnceVir 5–7 mo 12 mo 21–35 dz 42–70 dz 6–12 3 yrs 3
Intervals given in months (mo) unless indicated as years (yrs) or days (d).
yInterval of 3 yrs in persons  50 years of age (in Austria an interval of 3 y for persons 60 years of age.
zDouble dose of total 1.0 ml.
For FSME-immun, the licensed rapid scheme is only licensed for adults. For FSME-Immun and Encepur, after the first booster dose, intervals of 5 years are now recom-
mended by the manufacturers for persons below 50 and 60 years of age, respectively.
Adapted from Kollaritsch.10
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which manifests as encephalitis, meningitis, or acute flaccid
paralysis that may result in respiratory failure. Some patients
with WNND experience long-term neurological dysfunction
requiring assistance with daily activities.17 Persons of all ages
are susceptible to WNV infection, but the incidence of neuroin-
vasive disease and death increases with age. The incidence of
WNND is also higher in immunocompromised patients, and it
is slightly higher in male patients.25 Until the mid-1990s,
human WNV cases were sporadic with mild manifestations.
During the 1990’s, more severe outbreaks with increased neuro-
invasive disease were seen in North Africa, the US and southern
Europe. Following the introduction of WNV into the US in
1999, the number of human infections there rose dramatically,
peaking in 2002–2003 (2003: 9,862 cases).26 The case-fatality
rate was reported to be 4.2% in the US, whereas the case-fatality
rate among patients with WNND was 9.6%.17 The case fatality
rates of <40-year-old, 40–59-year-old, and60-year-old dis-
playing neurological diseases were 0.8%, 3%, and 17%, respec-
tively.1 Following the WNV outbreak in Greece with 262
reported cases in 2010, the European Union has begun efforts
to improve surveillance. In 2010–2012, southern European and
neighboring countries demonstrated a total of 2,414 WNV cases
with 127 associated deaths resulting in a case-fatality rate of
5.3%, similar to the rate observed in the United States.17 The
highest notification rate was reported in the 65-year-old age
group (0.04 cases per 100,000,). Only one case was reported
among children under the age of 15 years (Fig. 2).27
Immunity against WNV
Antibodies against WNV, measured with immunoassays
using WNV recombinant proteins (premembrane/envelope),
start to appear about three to seven days following
infection.18,29 WNV-specific IgM antibodies, but also IgA,
have been shown to be detectable on day 3 after being tested
positive for WNV and persist for at least 6 months after infec-
tion.29 The diagnosis of WNV infection generally relies on the
demonstration of specific antibodies against WNV in serum
or cerebrospinal fluid, although cross-reactivity with infec-
tions caused by other flaviviruses is a problem in serological
diagnostic tests.18 Animal experiments indicate that specific
antibodies are responsible for terminating viremia, while
CD8C T cells have an important function in clearing infec-
tion from tissues and preventing viral persistence.30 However,
it cannot be excluded that T cells, apart from recovery of
WNV encephalitis, may also cause immunopathology based
on experiments in CD8C deficient mice.18,31 A number of
animal studies using passive immunization have shown that
transfer of neutralizing antibodies to na€ıve animals is suffi-
cient for protection against lethal WNV infection.17
Vaccines in clinical development
The increasing incidence of West Nile neuro-invasive disease
(WNND), new outbreaks, the endemic virus circulation in tem-
perate areas, and lack of specific therapeutic treatments for
humans have promoted research and development activities on
vaccines against WNV. Although there are several veterinary
vaccines for horses licensed.32 there is no human WNV vaccine
available yet.
Various vaccine concepts against WNV are in development,
including DNA-vectored vaccines, live chimeric/recombinant
vaccines expressing WNV protein(s), live attenuated vaccines,
subunit (i.e. protein-, peptide-, or virus-like particle based) vac-
cines or inactivated whole virus vaccines. Ideally, WNV vaccine
needs to protect against all WNV genotypes that can
Figure 2. Distribution of West Nile fever cases by affected areas in Europe and Mediterranean basis in 2017 (current season) and previous seasons; updated 7 September
2017.28
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cause WNND in humans. This supports the development of a
whole virus vaccine, either inactivated or live-attenuated, in
order to achieve a broad coverage of the vaccine.
So far, some vaccine concepts have reached the early clinical
phase of development, but none of them has progressed any
further. The WNV vaccine concepts, including antigen targets
that have reached early clinical stage are listed in Table 2. All
tested vaccines appeared to have a good safety profile, and sero-
conversion rates showed to be high. Geometric mean antibody
titers, although not always published, seem to vary considerably
between subjects.33–39
A hurdle for human WNV vaccine development is the lim-
ited feasibility to perform phase III efficacy trials, because of
the relatively low incidence and unpredictable sporadic nature
of WNV outbreaks. This poses not only a challenge for clinical
study design, but also for implementation of a new WNV vac-
cine.40 This may be partly overcome by maintaining and/or
strengthening the surveillance efforts, and thereby planning tri-
als in regions of high WNV incidence, and monitoring for vac-
cine efficacy over a prolonged period of time (possibly 1 to
3 years).17
Discussion
Increasing risk for flaviviruses in Europe and surveillance
Infected mosquito vectors might be introduced in EU countries
via international travel and commerce with other continents
where flaviviruses are endemic. Moreover, rising temperatures
will expand geographic areas and widen Europe’s seasonal win-
dow for the potential spread of vector-borne viral diseases. For
instance, Culex pipiens mosquitoes that were collected in 2010–
2011 for screening in Northern Italy appeared to be infected
with JEV. This finding may indicate a wider range of distribu-
tion of the vector and virus and a potential public health threat
in Europe.3 In 2012–2013, a dengue outbreak occurred in
Madeira, Portugal with 1080 confirmed cases. The main vector
for dengue, Aedes aegypti, was detected for the first time in
Madeira in 2005.4 Other human pathogenic flaviviruses exist
that rarely cause human disease, such as usutu virus. The usutu
virus have been detected in Austria, Italy, Germany, Spain,
Hungary, Switzerland, Poland, England, Czech Republic,
Greece, and Belgium, where it caused unusual mortality in
birds.41 Reports on clinically apparent human usutu virus infec-
tions, however, are scarce and only four cases are described so
far in the literature.42 Furthermore, it has been shown that
other flaviviruses can cause human disease in Europe by tick
bite transmission, i.e. Omsk haemorrhagic fever virus, louping
ill virus, and Powassan virus. Omsk haemorrhagic fever virus
infections seemed to be confined to some regions of western
Siberia. In more recent years, most human cases have been
related to direct contact with musk-rats. Only few cases of dis-
ease caused by louping ill virus and Powassan virus have been
reported in the literature.15
The surveillance of TBE in the European countries is not
uniform and not always mandatory. Efforts to reach a final
diagnosis, especially in less severe cases, vary at present as well
as the awareness of the disease in low endemic regions. An ade-
quate national surveillance of TBE cases is important and
should be recommended in all European countries. The unpre-
dictable nature of WNV outbreaks necessitates the establish-
ment and maintenance of surveillance systems capable of
detecting increases in WNV transmission activity. In addition,
an active animal health surveillance system to detect new
WNV cases in birds and horses is essential.
Vaccination strategy
Tick-borne encephalitis (TBE) is a substantial public health
problem in many parts of Europe. With various safe and effec-
tive vaccines currently available, vaccination is the most effec-
tive protection against TBE. However, in most endemic
countries vaccination coverage is too low to reduce the TBE
burden significantly. Among all European countries, vaccina-
tion coverage is highest in Austria, where 85% of the total
population have received >1 doses of the vaccine.16 This high
vaccination coverage has led to a dramatic decline in the overall
incidence of TBE in Austria. The field effectiveness of the vac-
cine for preventing disease appeared to be high, i.e. 96%–99%
after regular vaccination and best-case assumptions. Even
among persons with a history of irregular vaccinations, the
average protection rate was still >90%. In Austria during
2000–2011, it was calculated that vaccination prevented
>4,000 cases of TBE.16 Moreover, vaccine effectiveness is excel-
lent among elderly persons, for whom risk for severe forms of
TBE and neuropathological sequelae is highest.16 This indicates
that TBE vaccination is an excellent way to prevent disease in
all age groups. However, important factors to consider before
implementation of vaccination, are: incidence threshold, which
WHO recommends to be 5/100,000 and cost-effectiveness. Yet,
incidence could be relevant on a regional, rather than a national
scale, and cost-effectiveness could be considered based on age
groups, rather than the whole population, as shown by an Esto-
nian study where vaccination of the 50 year olds was more
cost-effective from the health care perspective than vaccination
of the whole population.43
Severe neuroinvasive disease caused by WNV occurs in less
than 1% of infected persons and mostly affects elderly and
immunocompromised individuals.25 Universal WNV vaccina-
tion is therefore unlikely to be cost-effective. Especially consid-
ering that almost 3 million Americans have likely been infected
with WNV, but most patients are not seeking medical care
because of asymptomatic or mildly symptomatic disease.17
Therefore, further studies are needed to determine if targeted
vaccine campaigns focused on at-risk groups or geographical
regions will provide a favorable cost-effectiveness. These studies
should preferably include not only direct health care costs but
also costs associated with productivity loss, WNV surveillance,
prevention, and outbreak response.
Summarizing, climate change, virus evolution, and social
factors may lead to further spread of vector-borne infectious
diseases in the future. It remains to be seen whether (sub)tropi-
cal diseases such as yellow fever, dengue and Zika will emerge
in Europe, but considering the fact that the vectors are already
present and the expected increase in global temperatures there
is a theoretical risk. Therefore, an adequate vector-, animal
health- and human-surveillance system for rising and emerging
endemic flaviviruses within Europe is essential. Vaccination is
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considered the most important approach to prevent flavivirus
infections and vaccine development should be supported.
Implementation of vaccination against endemic flaviviruses
should be based on favorable cost-effectiveness estimates per
region and per target group.
Disclosure of potential conflicts of interest
No potential conflicts of interest were disclosed.
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